scholarly journals Fractionated stereotactic radiotherapy for uveal melanoma: Long‐term outcome and control rates

2021 ◽  
Author(s):  
Jackelien G. M. van Beek ◽  
Caroline M. van Rij ◽  
Sara J. Baart ◽  
Serdar Yavuzyigitoglu ◽  
Michael J. Bergmann ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Stereotactic Radiotherapy ◽  
Fractionated Stereotactic Radiotherapy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
And Control

Fractionated stereotactic radiotherapy in low-grade astrocytomas: Long-term outcome and prognostic factors

2003 ◽  
Vol 57 (4) ◽  
pp. 996-1003 ◽  
Author(s):  
Christian Plathow ◽  
Daniela Schulz-Ertner ◽  
Christoph Thilman ◽  
Ivan Zuna ◽  
Mathias Lichy ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Stereotactic Radiotherapy ◽  
Fractionated Stereotactic Radiotherapy ◽  
Low Grade ◽  
Term Outcome ◽  
Long Term Outcome

Fractionated stereotactic radiotherapy of optic pathway gliomas: Tolerance and long-term outcome

2005 ◽  
Vol 62 (3) ◽  
pp. 814-819 ◽  
Author(s):  
Stephanie E. Combs ◽  
Daniela Schulz-Ertner ◽  
Dimos Moschos ◽  
Christoph Thilmann ◽  
Peter E. Huber ◽  
...  
Keyword(s):  
Stereotactic Radiotherapy ◽  
Fractionated Stereotactic Radiotherapy ◽  
Optic Pathway ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Optic Pathway Gliomas

scholarly journals The Long-term Outcome of CyberKnife-Based Stereotactic Radiotherapy for Intra/ Extracranial Non-Vestibular Schwannomas: A Single-Center Experience

2021 ◽  
Author(s):  
Sukwoo Hong ◽  
Kenji Kagawa ◽  
Kengo Sato ◽  
Ryutaro Nomura ◽  
Shunsuke Ichi
Keyword(s):  
Stereotactic Radiotherapy ◽  
Significant Risk ◽  
Progression Free Survival ◽  
Target Volume ◽  
Vestibular Schwannomas ◽  
P Value ◽  
Tumor Extension ◽  
Term Outcome ◽  
Long Term Outcome

Abstract Background The long-term outcomes of CyberKnife-based hypofractionated stereotactic radiotherapy (SRT) for intra/ extracranial non-vestibular schwannomas (nVS) need to be accumulated. Method Patients who received SRT by CyberKnife for nVS from 2010 to 2019 were retrospectively reviewed. Results A total of 45 patients with nVS were identified. The mean age was 53 (± 18) years old, and 23 patients (51%) were female. Twenty-nine patients (64%) had previous procedures. As for the tumor extension, 22 (49%) nVS were classified as primary intracranial, five (11%) were classified as intra/ extracranial (dumbbell shape), and 18 (40%) were classified as primary extracranial. The median prescribed dose, covering 95% of the planning target volume, was 21 (IQR 21 – 25) Gy, and the median target volume was 7 (IQR 3.6-13.1) cm3. The local control rate of nVS for patients without neurofibromatosis type 2 (NF2) was 100%. Old age (OR 0.92, p-value 0.03) and previous surgery (OR 0.02, p-value 0.02) were significant risk factors for no symptomatic improvement. The progression-free survival was 74 (±33) months clinically and 69 (IQR 36 – 94) months radiologically. During follow-up, two cases (4%) with NF2 resulted in treatment failure, 13 cases (41%) resulted in transient tumor expansion (TTE), 10 (22%) suffered from transient adverse radiation effect (ARE), and two (4%) resulted in permanent ARE. Conclusions Hypofractionated SRT for head, neck, and spine nVS was an effective treatment regardless of tumor extension relative to the cranium. Although the risk of permanent ARE was low, some patients experienced transient clinical worsening due to TTE.

scholarly journals The Long-Term Outcome of CyberKnife-Based Stereotactic Radiotherapy for Intra/ Extracranial Non-Vestibular Schwannomas: A Single-Center Experience

2022 ◽  
Author(s):  
Sukwoo Hong ◽  
Kenji Kagawa ◽  
Kengo Sato ◽  
Ryutaro Nomura ◽  
Shunsuke Ichi
Keyword(s):  
Stereotactic Radiotherapy ◽  
Significant Risk ◽  
Progression Free Survival ◽  
Target Volume ◽  
Vestibular Schwannomas ◽  
P Value ◽  
Tumor Extension ◽  
Term Outcome ◽  
Long Term Outcome

Abstract The long-term outcomes of CyberKnife-based hypofractionated stereotactic radiotherapy (SRT) for intra/ extracranial non-vestibular schwannomas (nVS) need to be accumulated. Patients who received SRT by CyberKnife for nVS from 2010 to 2019 were retrospectively reviewed. A total of 45 patients with nVS were identified. The mean age was 53 (± 18) years old, and 23 patients (51%) were female. Twenty-nine patients (64%) had previous procedures. As for the tumor extension, 22 (49%) nVS were classified as primary intracranial, five (11%) were classified as intra/ extracranial (dumbbell shape), and 18 (40%) were classified as primary extracranial. The median prescribed dose, covering 95% of the planning target volume, was 21 (IQR 21 – 25) Gy, and the median target volume was 7 (IQR 3.6-13.1) cm3. The local control rate of nVS for patients without neurofibromatosis type 2 (NF2) was 100%. Old age (OR 0.92, p-value 0.03) and previous surgery (OR 0.02, p-value 0.02) were significant risk factors for no symptomatic improvement. The progression-free survival was 74 (±33) months clinically and 69 (IQR 36 – 94) months radiologically. During follow-up, two cases (4%) with NF2 resulted in treatment failure, 13 cases (41%) resulted in transient tumor expansion (TTE), 10 (22%) suffered from transient adverse radiation effect (ARE), and two (4%) resulted in permanent ARE. Hypofractionated SRT by CyberKnife for head, neck, and spine nVS was an effective treatment regardless of tumor extension relative to the cranium. Although the risk of permanent ARE was low, some patients experienced transient clinical worsening due to TTE.

Sign in / Sign up

Export Citation Format

Share Document